Seema Kantak

Seema Kantak

Company: Exelixis

Job title: Vice President, Biologics & Biotherapeutics


Discussing XB002, a Tissue- Factor-Targeted Antibody Drug Conjugate for the Treatment of Solid Tumors 12:30 pm

• XB002 is an ADC designed to improve on the therapeutic potential of ADCs that target TF • XB002 is a high affinity ADC with the Zymelink Aurastatin linkerpayload • Presenting efficacy, tolerability and exposure of XB002 in preclinical studiesRead more

day: day 2 track 2

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.